Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile

Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat Rev Cancer, 13, 714, 10.1038/nrc3599

Muñoz-Pinedo, 2012, Cancer metabolism: current perspectives and future directions, Cell Death Dis, 3, e248, 10.1038/cddis.2011.123

Butler, 2013, Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance, Cancer Res, 73, 2709, 10.1158/0008-5472.CAN-12-3009

Galluzzi, 2013, Metabolic targets for cancer therapy, Nat Rev Drug Discov, 12, 829, 10.1038/nrd4145

Sotgia, 2013, Cancer metabolism: new validated targets for drug discovery, Oncotarget, 4, 1309, 10.18632/oncotarget.1182

Zhao, 2013, Targeting cellular metabolism to improve cancer therapeutics, Cell Death Dis, 4, e532, 10.1038/cddis.2013.60

Menendez, 2013, The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells, Cell Cycle, 12, 1166, 10.4161/cc.24479

Cufí, 2013, The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer, Sci Rep, 3, 2469, 10.1038/srep02469

Cufí, 2012, Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment, Oncotarget, 3, 1600, 10.18632/oncotarget.742

Cufi, 2012, Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts, Oncotarget, 3, 395, 10.18632/oncotarget.488

Hirsch, 2009, Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission, Cancer Res, 69, 7507, 10.1158/0008-5472.CAN-09-2994

Iliopoulos, 2011, Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types, Cancer Res, 71, 3196, 10.1158/0008-5472.CAN-10-3471

Skinner, 2012, TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence, Clin Cancer Res, 18, 290, 10.1158/1078-0432.CCR-11-2260

Storozhuk, 2013, Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK, Br J Cancer, 108, 2021, 10.1038/bjc.2013.187

Zannella, 2013, Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response, Clin Cancer Res, 19, 6741, 10.1158/1078-0432.CCR-13-1787

Lonardo, 2013, Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells, PLoS One, 8, e76518, 10.1371/journal.pone.0076518

Pollak, 2013, Potential applications for biguanides in oncology, J Clin Invest, 123, 3693, 10.1172/JCI67232

Morgillo, 2013, Metformin in lung cancer: rationale for a combination therapy, Expert Opin Investig Drugs, 22, 1401, 10.1517/13543784.2013.828691

Hirsch, 2013, Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth, Proc Natl Acad Sci U S A, 110, 972, 10.1073/pnas.1221055110

Komurov, 2012, The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells, Mol Syst Biol, 8, 596, 10.1038/msb.2012.25

Locasale, 2012, Metabolic rewiring drives resistance to targeted cancer therapy, Mol Syst Biol, 8, 597, 10.1038/msb.2012.30

DeBerardinis, 2008, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation, Cell Metab, 7, 11, 10.1016/j.cmet.2007.10.002

Jones, 2009, Tumor suppressors and cell metabolism: a recipe for cancer growth, Genes Dev, 23, 537, 10.1101/gad.1756509

Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809

Ward, 2012, Metabolic reprogramming: a cancer hallmark even warburg did not anticipate, Cancer Cell, 21, 297, 10.1016/j.ccr.2012.02.014

Martin-Castillo, 2010, Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology, Ann Oncol, 21, 187, 10.1093/annonc/mdp494

Martin-Castillo, 2010, Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena, Cell Cycle, 9, 1057, 10.4161/cc.9.6.10994

Vazquez-Martin, 2011, The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells, Breast Cancer Res Treat, 126, 355, 10.1007/s10549-010-0924-x

Vazquez-Martin, 2010, Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells, Curr Mol Med, 10, 674, 10.2174/156652410792630625

Del Barco, 2011, Metformin: multi-faceted protection against cancer, Oncotarget, 2, 896, 10.18632/oncotarget.387

Oliveras-Ferraros, 2012, Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation, Cell Cycle, 11, 865, 10.4161/cc.11.5.19252

Cufí, 2012, Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205, Cell Cycle, 11, 1235, 10.4161/cc.11.6.19665

Menendez, 2012, Metformin is synthetically lethal with glucose withdrawal in cancer cells, Cell Cycle, 11, 2782, 10.4161/cc.20948

Corominas-Faja, 2012, Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs, Aging (Albany NY), 4, 480, 10.18632/aging.100472

Vazquez-Martin, 2012, Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency, Sci Rep, 2, 964, 10.1038/srep00964

Menendez, 2012, One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin, Aging (Albany NY), 4, 894, 10.18632/aging.100523

Cufí, 2013, Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin, Oncotarget, 4, 1484, 10.18632/oncotarget.1234

Yamaguchi, 2012, Finding a Panacea among combination cancer therapies, Cancer Res, 72, 18, 10.1158/0008-5472.CAN-11-3091

Yamaguchi, 2012, Challenges in targeting cancer metabolism for cancer therapy, EMBO Rep, 13, 1034, 10.1038/embor.2012.176

Robinson, 2012, Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL, Oncogene, 31, 4996, 10.1038/onc.2012.13

Ros, 2012, Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival, Cancer Discov, 2, 328, 10.1158/2159-8290.CD-11-0234

Diamandis, 2002, Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma, Cancer Res, 62, 295

Nakamura, 2003, The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia, Cancer Res, 63, 6543

Paliouras, 2007, Human tissue kallikreins: the cancer biomarker family, Cancer Lett, 249, 61, 10.1016/j.canlet.2006.12.018

Kontos, 2012, Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers, Clin Chem Lab Med, 50, 1877, 10.1515/cclm-2012-0247

Borgoño, 2004, Human tissue kallikreins: physiologic roles and applications in cancer, Mol Cancer Res, 2, 257, 10.1158/1541-7786.257.2.5

Puente, 2003, Human and mouse proteases: a comparative genomic approach, Nat Rev Genet, 4, 544, 10.1038/nrg1111

Quesada, 2009, The Degradome database: mammalian proteases and diseases of proteolysis, Nucleic Acids Res, 37, D239, 10.1093/nar/gkn570

Ordóñez, 2009, Proteolytic systems: constructing degradomes, Methods Mol Biol, 539, 33, 10.1007/978-1-60327-003-8_2

Fraile, 2013, Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas, Oncotarget, 4, 1931, 10.18632/oncotarget.1303

Shahinian, 2014, Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells, Mol Oncol, 8, 68, 10.1016/j.molonc.2013.09.003

Sano, 2007, Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3, Int J Oncol, 30, 1493

Santamaría, 1999, Molecular cloning and structural and functional characterization of human cathepsin F, a new cysteine proteinase of the papain family with a long propeptide domain, J Biol Chem, 274, 13800, 10.1074/jbc.274.20.13800

Krueger, 2001, Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype, Cancer Gene Ther, 8, 522, 10.1038/sj.cgt.7700341

Vazquez-Ortiz, 2005, Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer, BMC Cancer, 5, 68, 10.1186/1471-2407-5-68

Mohamed, 2006, Cysteine cathepsins: multifunctional enzymes in cancer, Nat Rev Cancer, 6, 764, 10.1038/nrc1949

López-Otín, 2007, Emerging roles of proteases in tumour suppression, Nat Rev Cancer, 7, 800, 10.1038/nrc2228

Palermo, 2008, Cysteine cathepsin proteases as pharmacological targets in cancer, Trends Pharmacol Sci, 29, 22, 10.1016/j.tips.2007.10.011

Obermajer, 2008, Role of cysteine cathepsins in matrix degradation and cell signalling, Connect Tissue Res, 49, 193, 10.1080/03008200802143158

Abdulghani, 2010, TRAIL receptor signaling and therapeutics, Expert Opin Ther Targets, 14, 1091, 10.1517/14728222.2010.519701

Allen, 2012, Regulation of the human TRAIL gene, Cancer Biol Ther, 13, 1143, 10.4161/cbt.21354

Walczak, 2013, Death receptor-ligand systems in cancer, cell death, and inflammation, Cold Spring Harb Perspect Biol, 5, a008698, 10.1101/cshperspect.a008698

Dimberg, 2013, On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics, Oncogene, 32, 1341, 10.1038/onc.2012.164

Crowder, 2012, Caspase-8 regulation of TRAIL-mediated cell death, Exp Oncol, 34, 160

Han, 2008, Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells, J Biol Chem, 283, 19665, 10.1074/jbc.M710169200

Hou, 2008, Enhancement of tumor-TRAIL susceptibility by modulation of autophagy, Autophagy, 4, 940, 10.4161/auto.6769

Herrero-Martín, 2009, TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells, EMBO J, 28, 677, 10.1038/emboj.2009.8

Hou, 2010, Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis, Autophagy, 6, 891, 10.4161/auto.6.7.13038

Levine, 2008, Bcl-2 family members: dual regulators of apoptosis and autophagy, Autophagy, 4, 600, 10.4161/auto.6260

Germain, 2010, Dining in with BCL-2: new guests at the autophagy table, Clin Sci (Lond), 118, 173, 10.1042/CS20090310

Zhou, 2011, Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis, FEBS J, 278, 403, 10.1111/j.1742-4658.2010.07965.x

He, 2012, Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation, Autophagy, 8, 1811, 10.4161/auto.22145

Chen, 2011, A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma, Mod Pathol, 24, 175, 10.1038/modpathol.2010.193

Nakanishi, 2013, Dclk1 distinguishes between tumor and normal stem cells in the intestine, Nat Genet, 45, 98, 10.1038/ng.2481

Sureban, 2013, DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer, PLoS One, 8, e73940, 10.1371/journal.pone.0073940

Bailey, 2014, DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer, Gastroenterology, 146, 245, 10.1053/j.gastro.2013.09.050

Brabletz, 2005, Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression, Nat Rev Cancer, 5, 744, 10.1038/nrc1694

Wellner, 2009, The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs, Nat Cell Biol, 11, 1487, 10.1038/ncb1998

Brabletz, 2012, To differentiate or not--routes towards metastasis, Nat Rev Cancer, 12, 425, 10.1038/nrc3265

Brabletz, 2012, EMT and MET in metastasis: where are the cancer stem cells?, Cancer Cell, 22, 699, 10.1016/j.ccr.2012.11.009

Nomura, 2010, Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis, Cell, 140, 49, 10.1016/j.cell.2009.11.027

Ye, 2011, Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer, Cancer Lett, 307, 6, 10.1016/j.canlet.2011.03.007

Nomura, 2011, Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer, Chem Biol, 18, 846, 10.1016/j.chembiol.2011.05.009

Fowler, 2012, Monoacylglycerol lipase - a target for drug development?, Br J Pharmacol, 166, 1568, 10.1111/j.1476-5381.2012.01950.x

Mulvihill, 2013, Therapeutic potential of monoacylglycerol lipase inhibitors, Life Sci, 92, 492, 10.1016/j.lfs.2012.10.025

Louie, 2013, Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids, Biochim Biophys Acta, 1831, 1566, 10.1016/j.bbalip.2013.07.008

Smyth, 2004, The extracellular matrix gene Frem1 is essential for the normal adhesion of the embryonic epidermis, Proc Natl Acad Sci U S A, 101, 13560, 10.1073/pnas.0402760101

Pavlakis, 2011, The role of Fras1/Frem proteins in the structure and function of basement membrane, Int J Biochem Cell Biol, 43, 487, 10.1016/j.biocel.2010.12.016

Ji, 2013, Wnt1 inducible signalling pathway protein-2 (WISP-2/CCN5): Roles and regulation in human cancers, Oncol Rep, 10.3892/or.2013.2909

Russo, 2010, CCN5: biology and pathophysiology, J Cell Commun Signal, 4, 119, 10.1007/s12079-010-0098-7

Fabbretti, 1995, Apoptotic phenotype induced by overexpression of wild-type gas3/PMP22: its relation to the demyelinating peripheral neuropathy CMT1A, Genes Dev, 9, 1846, 10.1101/gad.9.15.1846

Li, 2013, mda-7/IL-24 Expression inhibits breast cancer through upregulation of growth arrest-specific gene 3 (gas3) and disruption of β1 integrin function, Mol Cancer Res, 11, 593, 10.1158/1541-7786.MCR-12-0496

Kim, 2013, Loss of S100A14 expression is associated with the progression of adenocarcinomas of the small intestine, Pathobiology, 80, 95, 10.1159/000342394

Sapkota, 2012, S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest, Oral Oncol, 48, 219, 10.1016/j.oraloncology.2011.10.001

Roll, 2013, Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation, Exp Mol Pathol, 95, 276, 10.1016/j.yexmp.2013.09.001

Menezes, 2012, Dickkopf1: a tumor suppressor or metastasis promoter?, Int J Cancer, 130, 1477, 10.1002/ijc.26449

Qi, 2012, Dickkopf-1 inhibits epithelial-mesenchymal transition of colon cancer cells and contributes to colon cancer suppression, Cancer Sci, 103, 828, 10.1111/j.1349-7006.2012.02222.x

Barbolina, 2013, Matrix rigidity activates Wnt signaling through down-regulation of Dickkopf-1 protein, J Biol Chem, 288, 141, 10.1074/jbc.M112.431411

DiMeo, 2009, A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer, Cancer Res, 69, 5364, 10.1158/0008-5472.CAN-08-4135

Mitra, 2010, DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype, J Biol Chem, 285, 24686, 10.1074/jbc.M109.094847

Marignac, 2013, Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming, Oncotarget

Erenpreisa, 2007, Cancer: a matter of life cycle?, Cell Biol Int, 31, 1507, 10.1016/j.cellbi.2007.08.013

Salmina, 2010, Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells, Exp Cell Res, 316, 2099, 10.1016/j.yexcr.2010.04.030

Erenpreisa, 2011, Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation, Cell Biol Int, 35, 687, 10.1042/CBI20100762

Erenpreisa, 2013, Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal, Cancer Cell Int, 13, 92, 10.1186/1475-2867-13-92